Abound Wealth Management Catalyst Pharmaceuticals, Inc. Transaction History
Abound Wealth Management
- $354 Billion
- Q2 2025
A detailed history of Abound Wealth Management transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Abound Wealth Management holds 5 shares of CPRX stock, worth $111. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5
Previous 6
16.67%
Holding current value
$111
Previous $146,000
25.34%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding CPRX
# of Institutions
384Shares Held
100MCall Options Held
37KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$415 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.5MShares$189 Million0.0% of portfolio
-
State Street Corp Boston, MA5.53MShares$123 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.42MShares$76 Million2.1% of portfolio
-
Goldman Sachs Group Inc New York, NY3.14MShares$69.7 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.28B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...